CoChat

Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function

Open access
Wright, C. W. · 2005 · Journal of Clinical Investigation
Cited by 114

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Recent studies have shown that members of the inhibitor of apoptosis (IAP) protein family are highly expressed in several classes of cancer.The primary implication of these findings is that the elevated expression of IAPs is not coincidental but actually participates in oncogenesis by helping to allow the malignant cell to avoid apoptotic cell death.This concept, together with the discovery of several IAP-regulatory proteins that use a conserved mode of action, has stimulated a major effort by many research groups to devise IAP-targeting strategies as a means of developing novel antineoplastic drugs.In this Review, we consider the evidence both for and against the IAPs being valid therapeutic targets, and we describe the types of strategies being used to neutralize their functions. IAPs: structure and functionInhibitor of apoptosis (iap) genes were first described in insect viruses through a genetic screen to identify compensatory replacements for the loss of the baculoviral antiapoptotic p35 protein, which functions to block baculovirus-induced apoptosis during infection (1-3).Since the initial identification in baculoviruses, iap homologs have been identified across phyla from Caenorhabditis elegans and yeast to insects and mammals.As many as 8 human iap gene products have been identified (reviewed in ref. 4), XIAP (hILP/ MIHA/BIRC4), hILP-2 (TS-IAP), cellular IAP1 (c-IAP1/HIAP2/ MIHB/BIRC2), cellular IAP2 (c-IAP2/HIAP1/MIHC/BIRC3), melanoma-associated IAP (ML-IAP/Livin/KIAP1/BIRC7), neuronal apoptosis-inhibitory protein (NAIP/BIRC1), survivin (TIAP1/ BIRC5), and Apollon (BRUCE/BIRC6) (Figure 1A).These IAP proteins have been shown to play, for the most part, nonredundant cellular roles that range from apoptotic inhibition to the formation of the mitotic spindle during cytokinesis.For this reason, the term "IAP" is somewhat misleading, and these factors are often referred to as BIR-containing proteins, or BIRPs (5), a term derived from the presence of what has become the defining motif of this family, an approximately 65-residue domain rich in histidines and cysteines known as the baculovirus iap repeat (BIR).BIRPs contain 1-3 imperfectly repeated BIRs (Figure 1).Most of the IAP family members also harbor a RING domain at the carboxy terminus.The RING functions as an E3 ubiquitin ligase, which is preceded by ubiquitinactivating enzymes (E1) and ubiquitin-conjugating enzymes (E2) in the cascade of protein ubiquitination (6-9).E3 ubiquitin ligases provide specificity for the transfer of ubiquitin moieties onto the target protein.Therefore, IAP-mediated protein ubiquitination has a pivotal role in the regulation of apoptosis, allowing the IAP to control stability of itself and other proteins (10). IAPs in cancerMany studies have revealed a circumstantial association of IAPs and neoplasia (25).For example, XIAP levels are elevated in many Nonstandard abbreviations used: ASO, antisense oligonucleotide; BIR, baculovirus iap repeat; BIRP, BIR-containing protein; c-IAP, cellular IAP; Hid, head involution defective; IAP, inhibitor of apoptosis; IBM, IAP-binding motif; ML-IAP, melanoma-associated IAP; Rpr, reaper; Smac/DIABLO, second mitochondria-derived activator of caspase/direct IAP-binding protein with low pI; TRAIL, TNF-related apoptosis-inducing ligand.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci26251

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 114

Metadata

Authors
Wright, C. W.
Venue
Journal of Clinical Investigation
Published
2005-10-01
Volume
115
Issue
10
Pages
2673-2678
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2140433977
Cited by
114
References
4
FWCI
5.19
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. https://app.cochat.ai/papers/10.1172/jci26251
The paper
Wright, C. W. (2005). Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. Journal of Clinical Investigation. https://doi.org/10.1172/jci26251

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.